DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

2022/09/14 by Alexander Vishnevsky, Joan B. Soriano, Charlotte S. Ulrik +176
Biochemistry, Genetics and Molecular Biology · Medicine · #COVID-19 Clinical Research Studies #Inflammasome and immune disorders #Respiratory Support and Mechanisms

paper · pdf · doi:10.1007/s15010-022-01904-w

openalex publication_date 2022/09/14 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29

Citations

• Targeting the Microglial NLRP3 Inflammasome and Its Role in Parkinson's Disease
• A pneumonia outbreak associated with a new coronavirus of probable bat origin
• Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
• Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
• Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
• The Architecture of SARS-CoV-2 Transcriptome
• La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
• APACHE II